Łącze to prowadzi do strony internetowej firmy Bristol Myers Squibb, która może mieć inny cel, może mieć inny regulamin i jest udostępniana wyłącznie w celu umożliwienia kontaktu z firmą Bristol Myers Squibb.
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
Masz zamiar opuścić stronę bmsstudyconnect.com. Strona, do której prowadzi łącze, nie jest kontrolowana ani wspierana przez firmę Bristol Myers Squibb i nie ponosi ona odpowiedzialności za zawartość tej strony.
Masz zamiar opuścić stronę bmsstudyconnect.com. Strona, do której prowadzi łącze, nie jest kontrolowana ani wspierana przez firmę Bristol Myers Squibb i nie ponosi ona odpowiedzialności za zawartość tej strony.
Rekrutacja
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma - CA224-069
Zaktualizowano:
28 maj, 2025
|
ClinicalTrials.gov
Etap
Płeć
Zakres wieku
Lokalizacje
Rekrutacja
Inclusion Criteria: - Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT) - Pathologically confirmed high-risk, R/R non-Hodgkin lymphoma (NHL) after failure or non-response to first-line therapy, including but not limited to diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL) and primary mediastinal B-cell lymphoma - Pathologically confirmed recurrent cHL or NHL - Must have measurable [18F]fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) positive disease in both cHL and NHL cohorts Exclusion Criteria: - Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies - Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents - Prior autologous stem cell transplantation (HDCT/ASCT) - History of allogeneic bone marrow transplantation and with active graft versus host disease (GVHD) and prior history of Grade > 2 GVHD Other protocol-defined inclusion/exclusion criteria apply